newsfilter
← Earnings
Earnings Releases·

Talphera — Third Quarter 2026 Earnings Summary

  • Revenue for Q3 2026 was $0 compared to $1,000 in Q3 2025; net loss narrowed to $4.0 million ($0.05/share) from $4.4 million ($0.11/share) in the prior year period, while cash and investments declined to $14.2 million from $20.4 million at year-end 2025.
  • Management targets completion of the NEPHRO CRRT study by end of 2026, with enrollment exceeding 75% of the 70-patient target to provide over 80% statistical power, and updated research projects peak sales for nafamostat in CRRT at over $200 million.
  • Combined R&D and SG&A expenses rose to $4.1 million in Q3 2026 from $3.4 million in Q3 2025, driven by Niyad development activities and pre-launch commercial preparations.
  • The company plans to file a Form S-3 Shelf Registration Statement to replace its existing registration expiring November 30, 2026, and has received an ICD-10 code for nafamostat extracorporeal introduction.
Company
TALPHERA INC
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic